

## **PUBLIC INCLUDING PATIENTS AND JOURNALISTS' DISCLOSURE: ABPI METHODOLOGICAL NOTE**

### **1. ASTELLAS' COMMITMENT**

- 1.1 Astellas is a member company of the Association of the British Pharmaceutical Industry (“**ABPI**”). The ABPI Code (the “**ABPI Code**”) requires all member companies to make publicly available annually details of the fees for certain contracted services paid to members of the UK public, including patients and journalists.
- 1.2 Astellas discloses all Transfers of Value to members of the UK public, including patients and journalists in accordance with its commitment to the ABPI Code.
- 1.3 Astellas discloses all Transfers of Value to individual members of the UK public, including patients and journalists only. This does not include companies or other entities.
- 1.4 This note summarises the methodologies used by Astellas in preparing UK public, including patients and journalists disclosures pursuant to Clause 30 of the ABPI Code of Practice.

### **2. DEFINITIONS**

- 2.1 The ABPI Code defines the following terms:
  - “**Transfer of Value (ToV)**”: Direct and indirect ToV, whether in cash, in kind or otherwise, made, whether for promotional purposes or otherwise, in connection with the development and sale of POM exclusively for human use. Direct ToVs are those made directly by Astellas for the benefit of a Recipient. Indirect ToVs are those made on behalf of Astellas for the benefit of a Recipient, or those made through a Third Party and where Astellas knows or can identify the Recipient that will benefit from the Transfer of Value.
- 2.2 Disclosures must remain in the public domain for a minimum of three years and Astellas will document all Disclosures and retain the records for at least five years after the end of the calendar year to which they relate.

### **3. MEMBERS OF THE UK PUBLIC, INCLUDING PATIENTS AND JOURNALISTS' DISCLOSURE**

- 3.1 Astellas makes its disclosures annually in respect of each calendar year within the first six months after the end of the calendar year in which the transfers of value/ payments were made. Each report will be aggregated and include the following:
  - 3.1.1 Breakdown of the total number of members of the public, including patients and journalists contracted to perform services
  - 3.1.2 the total amount paid to each group per calendar year
  - 3.1.3 a description of the types of services provided
- 3.2 Fees and expenses will be disclosed separately

- 3.3 This does not apply to contactors/consultants who act on behalf of the company that employ them. E.g., An individual Patient/Member of the public contracted to speak at a meeting would be disclosable if they are discussing healthcare related topics however, a speaker acting on behalf of a company would not be.
- 3.4 The services may include speaking at meetings, assistance with training, writing articles and/or publications, participating in advisory boards, advising on the design of clinical trials and participating in Market Research where such participation involves remuneration and/or travel.

#### **4. COUNTRY OF DISCLOSURE**

Astellas has taken reasonable steps to disclose best estimates of fees paid to UK individuals by overseas affiliates, head offices in the UK or overseas and UK-based European offices. Astellas discloses Transfers of Value based on where the members of the public, including patients and journalists reside.

#### **5. CONTRACTS**

Astellas will record Transfers of Value relating to a contract in the year the Transfer of Value was made (which may be different to the year in which the contract was agreed).